Evidence map›Paper›PMID 35600330›Full record

ArticleEClinicalMedicine2022

Highly multiplexed immune repertoire sequencing links multiple lymphocyte classes with severity of response to COVID-19.

Richard Dannebaum, Phillip Suwalski, Hosseinali Asgharian, Gracie Du Zhipei, Hai Lin, January Weiner, Manuel Holtgrewe, Charlotte Thibeault, Melina Müller, Xiaomin Wang and 23 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Richard DannebaumRoche Sequencing Solutions Pleasanton, CA 94588, United States.
Phillip SuwalskiDepartment of Cardiology, Charité Universitätsmedizin Berlin, Berlin, DE 10117, Germany.
Hosseinali AsgharianRoche Sequencing Solutions Pleasanton, CA 94588, United States.
Gracie Du ZhipeiRoche Sequencing Solutions Pleasanton, CA 94588, United States.
Hai LinRoche Sequencing Solutions Pleasanton, CA 94588, United States.
January WeinerCore Unit Bioinformatics Berlin, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, DE 10178, Germany.
Manuel HoltgreweCore Unit Bioinformatics Berlin, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, DE 10178, Germany.
Charlotte ThibeaultDepartment of Infectious Diseases and Respiratory Medicine, Charité Universitätsmedizin Berlin, DE 12203, Germany.
Melina MüllerDepartment of Cardiology, Charité Universitätsmedizin Berlin, Berlin, DE 10117, Germany.
Xiaomin WangDepartment of Cardiology, Charité Universitätsmedizin Berlin, Berlin, DE 10117, Germany.
Zehra KaradenizDepartment of Cardiology, Charité Universitätsmedizin Berlin, Berlin, DE 10117, Germany.
Jacopo SaccomannoDepartment of Infectious Diseases and Respiratory Medicine, Charité Universitätsmedizin Berlin, DE 12203, Germany.
Jan-Moritz DoehnDepartment of Infectious Diseases and Respiratory Medicine, Charité Universitätsmedizin Berlin, DE 12203, Germany.
Ralf-Harto HübnerDepartment of Infectious Diseases and Respiratory Medicine, Charité Universitätsmedizin Berlin, DE 12203, Germany.
Bernd HinzmannSignature Diagnostics GmbH, DE 14473, Germany.
Anja BlüherSignature Diagnostics GmbH, DE 14473, Germany.
Sandra SiemannSignature Diagnostics GmbH, DE 14473, Germany.
Dilduz TelmanRoche Sequencing Solutions Pleasanton, CA 94588, United States.
Norbert SuttorpDepartment of Infectious Diseases and Respiratory Medicine, Charité Universitätsmedizin Berlin, DE 12203, Germany.
Martin WitzenrathDepartment of Infectious Diseases and Respiratory Medicine, Charité Universitätsmedizin Berlin, DE 12203, Germany.
Stefan HippenstielDepartment of Infectious Diseases and Respiratory Medicine, Charité Universitätsmedizin Berlin, DE 12203, Germany.
Carsten SkurkDepartment of Cardiology, Charité Universitätsmedizin Berlin, Berlin, DE 10117, Germany.
Wolfgang PollerDepartment of Cardiology, Charité Universitätsmedizin Berlin, Berlin, DE 10117, Germany.
Leif E SanderDepartment of Infectious Diseases and Respiratory Medicine, Charité Universitätsmedizin Berlin, DE 12203, Germany.
Dieter BeuleCore Unit Bioinformatics Berlin, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, DE 10178, Germany.
Florian KurthDepartment of Infectious Diseases and Respiratory Medicine, Charité Universitätsmedizin Berlin, DE 12203, Germany.
Toumy GuettoucheRoche Sequencing Solutions Pleasanton, CA 94588, United States.
Ulf LandmesserDepartment of Cardiology, Charité Universitätsmedizin Berlin, Berlin, DE 10117, Germany.
Jan BerkaRoche Sequencing Solutions Pleasanton, CA 94588, United States.
Khai LuongRoche Sequencing Solutions Pleasanton, CA 94588, United States.
Pa-COVID Study Group
Florian RubeltRoche Sequencing Solutions Pleasanton, CA 94588, United States.
Bettina HeideckerDepartment of Cardiology, Charité Universitätsmedizin Berlin, Berlin, DE 10117, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Disease progression of subjects with coronavirus disease 2019 (COVID-19) varies dramatically. Understanding the various types of immune response to SARS-CoV-2 is critical for better clinical management of coronavirus outbreaks and to potentially improve future therapies. Disease dynamics can be characterized by deciphering the adaptive immune response. Methods: In this cross-sectional study we analyzed 117 peripheral blood immune repertoires from healthy controls and subjects with mild to severe COVID-19 disease to elucidate the interplay between B and T cells. We used an immune repertoire Primer Extension Target Enrichment method (immunoPETE) to sequence simultaneously human leukocyte antigen (HLA) restricted T cell receptor beta chain (TRB) and unrestricted T cell receptor delta chain (TRD) and immunoglobulin heavy chain (IgH) immune receptor repertoires. The distribution was analyzed of TRB, TRD and IgH clones between healthy and COVID-19 infected subjects. Using McFadden's Adjusted R2 variables were examined for a predictive model. The aim of this study is to analyze the influence of the adaptive immune repertoire on the severity of the disease (value on the World Health Organization Clinical Progression Scale) in COVID-19. Findings: Combining clinical metadata with clonotypes of three immune receptor heavy chains (TRB, TRD, and IgH), we found significant associations between COVID-19 disease severity groups and immune receptor sequences of B and T cell compartments. Logistic regression showed an increase in shared IgH clonal types and decrease of TRD in subjects with severe COVID-19. The probability of finding shared clones of TRD clonal types was highest in healthy subjects (controls). Some specific TRB clones seems to be present in severe COVID-19 (Figure S7b). The most informative models (McFadden´s Adjusted R2=0.141) linked disease severity with immune repertoire measures across all three cell types, as well as receptor-specific cell counts, highlighting the importance of multiple lymphocyte classes in disease progression. Interpretation: Adaptive immune receptor peripheral blood repertoire measures are associated with COVID-19 disease severity. Funding: The study was funded with grants from the Berlin Institute of Health (BIH).

Indexed as

Clinical courseCOVID-19Immune receptorImmune repertoires

Identifiers

PMID35600330
PMCPMC9106482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.